The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
Open accessAbstract
Tumor cells with mutated PTEN proliferate in an EGFR-independent manner. Induction of PTEN sensitizes cells to EGFR inhibition, and the combination causes synergistic apoptosis. Synergy is due to inhibition of two parallel pathways that phosphorylate the proapoptotic protein BAD at distinct sites. Serine 112 phosphorylation is EGFR/MEK/MAPK dependent, whereas serine 136 phosphorylation is PI3K/Akt dependent. Either phosphorylation is sufficient to sequester BAD to 14-3-3. BAD is released and apoptosis is induced only if both serines are dephosphorylated in response to inhibition of both pathways. Reduction of BAD expression by RNA interference prevents apoptosis in response to pathway inhibition. Thus, BAD integrates the antiapoptotic effects of both pathways. Combined inhibition of EGFR and PI3K signaling may be a useful therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,595
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death
Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., & Korsmeyer, S. J. (1995) · Cell · doi:10.1016/0092-8674(95)90411-5 · Cited by 2,100
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,901
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
14-3-3 Proteins and Survival Kinases Cooperate to Inactivate BAD by BH3 Domain Phosphorylation
Datta, S. R., Katsov, A., Hu, L. S., Petros, A. M., Fesik, S. W., Yaffe, M. B., & Greenberg, M. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00006-x · Cited by 663
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661
Huang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M., & Sellers, W. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2110 · Cited by 575
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 555
Self-citationGarcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Self-citationEpidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase
Scheid, M. P., Schubert, K. M., & Duronio, V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.31108 · Cited by 384
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, R. B., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.200 · Cited by 305
Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P. G. Y., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. N., et al. (2001) · PubMed · Cited by 298
She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287
Self-citationRegulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
Fang, X., Yu, S., Eder, A., Mao, M., Bast, R. C., Boyd, D., & Mills, G. B. (1999) · Oncogene · doi:10.1038/sj.onc.1203076 · Cited by 266
Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205184 · Cited by 265
Self-citationEkstrand, A. J., Longo, N., Hamid, M. L., Olson, J. J., Liu, L., Collins, V. P., & James, C. D. (1994) · PubMed · Cited by 255
Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., & Murata, Y. (2000) · PubMed · Cited by 243
Rojas, M., Yao, S., & Lin, Y.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27456 · Cited by 235
Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., & Loeffler, J. S. (2002) · PubMed · Cited by 234
Gilmore, A. P., Valentijn, A. J., Wang, P., Ranger, A. M., Bundred, N., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J., & Streuli, C. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108863200 · Cited by 207
ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 205
Fernando, R. I., & Wimalasena, J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-11-0823 · Cited by 144
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 126
Self-citationMEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Sebolt–Leopold, J. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384439 · Cited by 123
Uzgare, A. R., & Isaacs, J. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0968 · Cited by 121
Nüsse, M., Beisker, W., Hoffmann, C., & Tárnok, A. (1990) · Cytometry · doi:10.1002/cyto.990110707 · Cited by 88
Bedogni, B., O’Neill, M. S., Welford, S. M., Bouley, D. M., Giaccia, A. J., Denko, N. C., & Powell, M. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3327 · Cited by 78
Markowitz, S. D., Myeroff, L. L., Cooper, M. J., Traicoff, J. L., Kochera, M., Lutterbaugh, J., Swiriduk, M., & Willson, J. K. V. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117048 · Cited by 65
Lee, H., Srinivas, H., Xia, D., Lu, Y., Superty, R., LaPushin, R., Gomez‐Manzano, C., Gal, A., Walsh, G. L., Force, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300997200 · Cited by 58
She, Q., Ma, W., Wang, M., Kaji, A., Ho, C., & Dong, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206370 · Cited by 57
Self-citationThomas, C. Y., Ely, G., James, D. C., Jenkins, R. B., Kastan, M. B., Jedlicka, A., Burger, P. C., & Wharen, R. E. (2001) · Acta Neuropathologica · doi:10.1007/s004010000332 · Cited by 29
Cited by
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Metadata
- Authors
- She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 8
- Issue
- 4
- Pages
- 287-297
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2122624068
- Cited by
- 421
- References
- 50
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.